Oct 25 2010
curasan AG, listed in the General Standard of the German Stock Exchange (ISIN: DE 000 549 453 8) has received European approval for its new granular bone regeneration material Ceracell®.
Hans Dieter Rössler, CEO of curasan AG, considers the CE-certification of Ceracell® to be another milestone in the implementation of the product offensive launched at the beginning of the year: “We are implementing our strategy of offering innovative biomaterials, customized to the needs of the users, both consistently and persistently. The launch of Ceracell® in the dental market is planned to coincide with the world’s largest international dental exhibition in Cologne (IDS) at the end of March next year, and it will be launched approximately three months later in the orthopaedic market.”
Ceracell® is a synthetic, completely absorbable and bioactive bone regeneration material. Although the porosity compared to Cerasorb® has been increased considerably yet again, the material has greater mechanical stability. Thanks to the spongy structure designed after human bones and an optimised formulation an increased number of bone-forming cells dock on Ceracell®, which leads to accelerated and qualitatively better bone regeneration. Ceracell® is especially suitable when the body’s own healing potency needs to be reinforced by substances for bone growth such as PRP, BMP, bone marrow or stem cells.